CF
ALLO icon

CNA Financial’s Allogene Therapeutics ALLO Stock Holding History

CNA Financial’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-17,476
Closed -$449K – 194
2021
Q3 		$449K Buy
17,476
+205
+1% +$4.87K 0.12% 168
2021
Q2 		$450K Buy
17,271
+2,295
+15% +$65.4K 0.13% 170
2021
Q1 		$529K Sell
14,976
-520
-3% -$17.5K 0.16% 155
2020
Q4 		$391K Buy
15,496
+4,186
+37% +$136K 0.12% 174
2020
Q3 		$427K Buy
11,310
+1,860
+20% +$70.1K 0.16% 145
2020
Q2 		$405K Buy
+9,450
New +$342K 0.16% 146

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CNA Financial's ALLO Position: Q4 2021 in Review

CNA Financial sold out of Allogene Therapeutics (ALLO) in Q4 2021, closing a stake of 17,476 shares — an estimated $449K sold.

CNA Financial first reported a position in ALLO in Q2 2020 and held it in 6 quarters. The position peaked at $529K in Q1 2021. 177 funds tracked by Wall St. Rank hold ALLO as of Q4 2021.

  • CNA Financial reported no remaining Allogene Therapeutics position as of Q4 2021 after selling out during the quarter.
  • CNA Financial sold 17,476 Allogene Therapeutics shares in Q4 2021, an estimated $449K.
  • CNA Financial first reported a position in Allogene Therapeutics in Q2 2020 and held it in 6 quarters.
  • CNA Financial's Allogene Therapeutics position peaked at $529K in Q1 2021.
  • 177 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2021.

Based on CNA Financial's 13F filing for Q4 2021, filed 11 Feb 2022.